The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.

Say goodbye to the classic ClinicalTrials.gov!

The classic ClinicalTrials.gov website will be retired on June 25, 2024. Please use the modernized ClinicalTrials.gov. For more information, see ClinicalTrials.gov Modernization.

Key Record Dates

ClinicalTrials.gov Identifier:	NCT05338775
Brief Title:	A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (TRIMM-3)

First Submitted :	March 31, 2022
First Submitted that Met QC Criteria :	April 20, 2022
First Posted :	April 21, 2022

Last Update Submitted that Met QC Criteria :	April 23, 2024
Last Update Posted :	April 24, 2024

To Top